EKF Insider Trading

Insider Ownership Percentage: 5.11%
Insider Buying (Last 12 Months): £56,000
Insider Selling (Last 12 Months): GBX 0

EKF Diagnostics Insider Trading History Chart

This chart shows the insider buying and selling history at EKF Diagnostics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

EKF Diagnostics Share Price & Price History

Current Price: GBX 28.41
Price Change: Price Decrease of -0.486 (-1.68%)
As of 06/14/2024 01:34 PM ET

This chart shows the closing price history over time for EKF up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

EKF Diagnostics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2024Christopher H B MillsInsiderBuy100,000GBX 26£26,000
1/9/2024Christopher H B MillsInsiderBuy100,000GBX 30£30,000
6/20/2022Julian BainesInsiderBuy11,000GBX 33£3,630
4/28/2022Christopher H B MillsInsiderBuy1,275,000GBX 35£446,250
11/8/2021Julian BainesInsiderSell250,000GBX 81£202,500
10/1/2021Christopher H B MillsInsiderSell637,500GBX 84£535,500
See Full Table

SEC Filings (Institutional Ownership Changes) for EKF Diagnostics (LON:EKF)

71.45% of EKF Diagnostics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

EKF Diagnostics logo
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
Read More on EKF Diagnostics

Today's Range

Now: GBX 28.41
Low: 28.32
High: 30.40

50 Day Range

MA: GBX 29.85
Low: 26.50
High: 33

52 Week Range

Now: GBX 28.41
Low: 22.20
High: 38.22


197,634 shs

Average Volume

338,180 shs

Market Capitalization

£128.92 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of EKF Diagnostics?

EKF Diagnostics' top insider investors include:
  1. Christopher H B Mills (Insider)
  2. Julian Baines (Insider)
Learn More about top insider investors at EKF Diagnostics.